Clinical research of retinal laser photocoagulation and Ranibizumab on the treatment of neovascular glaucoma

Abstract

AIM: To explore the improvement of visual function and the adverse reactions of retinal laser photocoagulation combined with ranibizumab for the treatment of neovascular glaucoma(NVG), to provide the basis for clinical treatment.METHODS: One hundred patients with 129 eyes in our hospital from January 2012 to June 2014 were selected. They were randomly divided into the observation group and the control group, 50 cases in each one. Patients in the control group(67 eyes)were treated with retinal laser photocoagulation, and those in the observation group(62 eyes)were given retinal laser photocoagulation combined with ranibizumab treatment. After the treatment, the degeneration of iris neovascularization, visual acuity, intraocular pressure, ocular fundus and the adverse reactions were evaluated. Optical coherence tomography(OCT)was used to detect retinal nerve fiber layer(RNFL)thickness and visual field defect. RESULTS: The degeneration rate of the iris neovascularization in the observation group was 95.2%(59/62), higher than that of the control group 83.6%(56/67)(PPPPPP>0.05).CONCLUSION: The treatment of NVG with laser photocoagulation combined with ranibizumab has good clinical efficacy, and can significantly improve the vision and retinal structure and function of the patients, and is safer.

Keywords

• retinal laser photocoagulation
• ranibizumab
• neovascular glaucoma
• optical coherence tomography